Genetic biomarkers and crucial cell subsets of iron metabolism in Beta-Thalassemia: insights from bioinformatics and experimental validation [0.03%]
血红素代谢紊乱β-地中海贫血遗传生物标志物和关键细胞亚群的生物信息学研究及实验验证
Renrong Wei,Dan Qiu,Xiangxing Zeng
Renrong Wei
Approximately 1.5% of individuals with hemoglobin disorders carry the β-thalassemia gene variant, impacting around 40,000 newborns annually. Given the incomplete understanding of β-thalassemia pathogenesis, there is an urgent need to iden...
Tandem autologous hematopoietic stem cell transplantation in multiple myeloma: A historical perspective and current challenges [0.03%]
自体造血干细胞移植在多发性骨髓瘤中的历史意义及当前挑战
Xueting Wang,Yushan Cui,Yaomei Wang et al.
Xueting Wang et al.
Multiple myeloma (MM) is a heterogeneous and relapse-prone hematologic malignancy that remains incurable. For newly diagnosed patients aged 70 years or younger, who are eligible for transplantation, autologous hematopoietic stem cell transp...
Access to hydroxyurea in Sub-Saharan Africa remains a neglected response to sickle cell disease: reply to use of hydroxyurea in French-speaking Sub-Saharan Africa article [0.03%]
羟脲在撒哈拉以南非洲的使用仍是应对镰状细胞病的一个被忽视的措施：对法语撒哈拉以南非洲使用羟脲文章的回复
Paulo João Ferreira de Almeida
Paulo João Ferreira de Almeida
Impact of best response to ibrutinib plus Bendamustine and rituximab on PFS in MCL: a secondary analysis of SHINE [0.03%]
伊布替尼联合苯达莫司汀和利妥昔单抗的最佳疗效对套细胞淋巴瘤患者无进展生存期的影响：SHINE研究的二次分析
Yuko Mishima,Daigo Hashimoto,Michiko Ichii et al.
Yuko Mishima et al.
Ibrutinib is a first-in-class oral inhibitor of Bruton's tyrosine kinase, which was investigated for the first-line treatment of mantle cell lymphoma (MCL) in the randomized, double-blind, phase 3 SHINE study. In SHINE, ibrutinib plus benda...
An unconquered challenge in MDS: review of pathophysiology, clinical manifestations, and management options of MDS with thrombocytopenia [0.03%]
低血小板减少单克隆造血干细胞病的病理生理、临床表现及治疗选择综述
Xiaoyi Chen,Mihir Shukla,Jun H Choi
Xiaoyi Chen
Myelodysplastic syndromes (MDS) is a heterogeneous group of myeloid clonal disorder resulting in bone marrow failure with a tendency to acute myeloid leukemia transformation. MDS is characterized by a variable degree of clonal cytopenia. Co...
Multicenter, real-world observational study of AVA therapy following ELT/HET switching in Chinese children with persistent/chronic primary ITP [0.03%]
中国儿童持续性/慢性特发性血小板减少性紫癜患者艾曲波帕治疗的真实世界研究
Jingjing Liu,Zhifa Wang,Nan Wang et al.
Jingjing Liu et al.
Avatrombopag (AVA), a second-generation thrombopoietin receptor agonist (TPO-RA), has demonstrated efficacy in pediatric persistent/chronic immune thrombocytopenia (ITP). However, critical evidence gaps persist regarding treatment-switching...
An international prognostic index to predict the early chemoimmunotherapy failure of diffuse large B-cell lymphoma [0.03%]
一项预测弥漫性大B细胞淋巴瘤早期化疗免疫治疗失败的国际型预后指数
Qifan Xu,Yang Li,Beibei Xin et al.
Qifan Xu et al.
Approximately 30-40% of diffuse large B-cell lymphoma (DLBCL) patients will develop relapse/refractory disease, who may benefit from novel therapies, such as CAR-T cell therapy. Thus, accurate identification of individuals at high risk of e...
Expanding the frontier of CAR therapy: comparative insights into CAR-T, CAR-NK, CAR-M, and CAR-DC approaches [0.03%]
CAR疗法的前沿拓展：CAR-T、CAR-NK、CAR-M和CAR-DC方法的比较研究
Yiling Zhang,Rong Hu,Xiaoling Xie et al.
Yiling Zhang et al.
Chimeric antigen receptor (CAR) therapies have demonstrated remarkable clinical efficacy in hematological malignancies, validating their therapeutic potential. However, challenges such as therapeutic resistance and limited accessibility hin...
An Italian real-world multicenter study of patients with refractory/relapsed functional high-risk multiple myeloma patients treated with second-line therapies [0.03%]
意大利真实世界多中心复发和难治性高危功能性多发性骨髓瘤患者二线治疗研究
Danilo De Novellis,Salvatore Palmieri,Stefano Rocco et al.
Danilo De Novellis et al.
Functional high risk multiple myeloma (FHRMM) remains a challenging entity with poor outcomes and limited survival, and there is no international consensus on optimal second-line therapeutic strategies in relapsed/refractory patients. In th...
Is splenectomy one of the contributory factors to pulmonary hypertension? An analysis of splenectomized hemolytic anemia and immune thrombocytopenia patients [0.03%]
脾切除与肺动脉高压发病相关吗？溶血性贫血和免疫性血小板减少症患者中行脾切除术患者的分析研究
Zeliha Birsin,Ayşe Salihoğlu,Kardelen Ohtaroğlu Tokdil et al.
Zeliha Birsin et al.
The development of pulmonary hypertension (PH) after splenectomy is one of the recently controversial issues. This study aims to investigate whether splenectomy itself is an independent risk factor for the development of PH or if the primar...